{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:51:44Z","timestamp":1791661904806,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2019\/35\/B\/NZ5\/04432"],"award-info":[{"award-number":["2019\/35\/B\/NZ5\/04432"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.biopha.2022.113544","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T01:03:30Z","timestamp":1660871010000},"page":"113544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["New potential treatment for cardiovascular disease through modulation of hemoglobin oxygen binding curve: Myo-inositol trispyrophosphate (ITPP), from cancer to cardiovascular disease"],"prefix":"10.1016","volume":"154","author":[{"given":"Marta","family":"Okni\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Mackiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Zajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Kieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"M\u0105czewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113544_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-1-4939-3023-4_13","article-title":"The pathway for oxygen: tutorial modelling on oxygen transport from air to mitochondrion: the pathway for oxygen","volume":"876","author":"Bassingthwaighte","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113544_bib2","first-page":"1","article-title":"Partial pressure of oxygen in the human body: a general review","volume":"9","author":"Ortiz-Prado","year":"2019","journal-title":"Am. J. Blood Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.113544_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-015-0178-6","article-title":"Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension: mitochondrial inhibition as driver of cardiac failure?","volume":"16","author":"Balestra","year":"2015","journal-title":"Respir. Res."},{"issue":"3","key":"10.1016\/j.biopha.2022.113544_bib4","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1183\/20734735.001415","article-title":"Relating oxygen partial pressure, saturation and content: the haemoglobin-oxygen dissociation curve","volume":"11","author":"Collins","year":"2015","journal-title":"Breathe"},{"key":"10.1016\/j.biopha.2022.113544_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110338","article-title":"Oxygen homeostasis and cardiovascular disease: a role for HIF?","volume":"128","author":"Li","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2022.113544_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2012.10.002","article-title":"Heart failure","volume":"1","author":"Braunwald","year":"2013","journal-title":"JACC Heart Fail."},{"issue":"1","key":"10.1016\/j.biopha.2022.113544_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-022-00909-8","article-title":"Coronary blood flow in heart failure: cause, consequence and bystander","volume":"117","author":"Heusch","year":"2022","journal-title":"Basic Res. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113544_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/01.CIR.66.1.143","article-title":"Arterial oxygenation and arterial oxygen transport in chronic myocardial failure at rest, during exercise and after hydralazine treatment","volume":"66","author":"Rubin","year":"1982","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.biopha.2022.113544_bib9","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/01.CIR.101.24.2803","article-title":"Impairment of ventilatory efficiency in heart failure: prognostic impact","volume":"101","author":"Kleber","year":"2000","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.biopha.2022.113544_bib10","doi-asserted-by":"crossref","first-page":"H1050","DOI":"10.1152\/ajpheart.00943.2011","article-title":"Muscle oxygen transport and utilization in heart failure: implications for exercise (in)tolerance","volume":"302","author":"Poole","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.biopha.2022.113544_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.878363","article-title":"Contribution of peripheral chemoreceptors to exercise intolerance in heart failure","volume":"13","author":"Kulej-Lyko","year":"2022","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113544_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cardfail.2012.11.005","article-title":"A possible role for systemic hypoxia in the reactive component of pulmonary hypertension in heart failure","volume":"19","author":"Taylor","year":"2013","journal-title":"J. Card. Fail."},{"issue":"2","key":"10.1016\/j.biopha.2022.113544_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension. A national prospective study","volume":"107","author":"Rich","year":"1987","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2022.113544_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijcard.2017.11.023","article-title":"Physiological insights of exercise hyperventilation in arterial and chronic thromboembolic pulmonary hypertension","volume":"259","author":"Farina","year":"2018","journal-title":"Int. J. Cardiol."},{"issue":"160","key":"10.1016\/j.biopha.2022.113544_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0284-2020","article-title":"Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms","volume":"30","author":"Malenfant","year":"2021","journal-title":"Eur. Respir. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2022.113544_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/hc0102.101509","article-title":"Gas exchange detection of exercise-induced right-to-left shunt in patients with primary pulmonary hypertension","volume":"105","author":"Sun","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.biopha.2022.113544_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191869","article-title":"Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension","volume":"13","author":"Khirfan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.113544_bib18","series-title":"Essentials of Medical Biochemistry","first-page":"489","article-title":"Hemoglobin","author":"Bhagavan","year":"2015"},{"issue":"2","key":"10.1016\/j.biopha.2022.113544_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0006-291X(67)90228-8","article-title":"The effect of organic phosphates from the human erythrocyte on the allosteric properties of hemoglobin","volume":"26","author":"Benesch","year":"1967","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2022.113544_bib20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1073\/pnas.59.2.526","article-title":"Reciprocal binding of oxygen and diphosphoglycerate by human hemoglobin","volume":"59","author":"Benesch","year":"1968","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"25","key":"10.1016\/j.biopha.2022.113544_bib21","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1056\/NEJM197006182822507","article-title":"Control of hemoglobin function within the red cell","volume":"282","author":"Bunn","year":"1970","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2022.113544_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/hrt.70.5.443","article-title":"Importance of oxygen-haemoglobin binding to oxygen transport in congestive heart failure","volume":"70","author":"Bersin","year":"1993","journal-title":"Br. Heart J."},{"issue":"1","key":"10.1016\/j.biopha.2022.113544_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.14214","article-title":"GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease","volume":"175","author":"Oksenberg","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113544_bib24","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00772.2016","article-title":"GBT1118, a potent allosteric modifier of hemoglobin O(2) affinity, increases tolerance to severe hypoxia in mice","volume":"313","author":"Dufu","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113544_bib25","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1152\/jappl.1985.58.6.1810","article-title":"Physiological effects of high-P50 erythrocyte transfusion on piglets","volume":"58","author":"Teisseire","year":"1985","journal-title":"J. Appl. Physiol."},{"issue":"19","key":"10.1016\/j.biopha.2022.113544_bib26","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1073\/pnas.84.19.6894","article-title":"Long-term physiological effects of enhanced O2 release by inositol hexaphosphate-loaded erythrocytes","volume":"84","author":"Teisseire","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.biopha.2022.113544_bib27","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bmcl.2005.01.064","article-title":"Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin","volume":"15","author":"Fylaktakidou","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"18","key":"10.1016\/j.biopha.2022.113544_bib28","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1002\/cbic.201000499","article-title":"Myo-inositol trispyrophosphate: a novel allosteric effector of hemoglobin with high permeation selectivity across the red blood cell plasma membrane","volume":"11","author":"Duarte","year":"2010","journal-title":"ChemBioChem"},{"key":"10.1016\/j.biopha.2022.113544_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2020.102520","article-title":"Modulation of red blood cell oxygen affinity with a novel allosteric modifier of hemoglobin is additive to the Bohr effect","volume":"87","author":"Evans","year":"2021","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2022.113544_bib30","doi-asserted-by":"crossref","first-page":"18427","DOI":"10.1038\/s41598-019-54965-7","article-title":"Metabolic alterations in acute myocardial ischemia-reperfusion injury and necrosis using in vivo hyperpolarized [1\u201313\u2009C] pyruvate MR spectroscopy","volume":"9","author":"Moon","year":"2019","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2022.113544_bib31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00109-013-0992-6","article-title":"Stable tumor vessel normalization with pO(2) increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment","volume":"91","author":"Kieda","year":"2013","journal-title":"J. Mol. Med."},{"issue":"42","key":"10.1016\/j.biopha.2022.113544_bib32","doi-asserted-by":"crossref","first-page":"15576","DOI":"10.1073\/pnas.0607109103","article-title":"Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes","volume":"103","author":"Kieda","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.biopha.2022.113544_bib33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/1566524018666181109121849","article-title":"Role of HIF-1 in cancer progression: novel insights. A review","volume":"18","author":"Pezzuto","year":"2018","journal-title":"Curr. Mol. Med."},{"issue":"17","key":"10.1016\/j.biopha.2022.113544_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137557","article-title":"HIF in the heart: development, metabolism, ischemia, and atherosclerosis","volume":"131","author":"Knutson","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.biopha.2022.113544_bib35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O'Reilly","year":"1997","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.biopha.2022.113544_bib36","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00109-007-0221-2","article-title":"Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome","volume":"85","author":"Teodoro","year":"2007","journal-title":"J. Mol. Med."},{"issue":"4","key":"10.1016\/j.biopha.2022.113544_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040992","article-title":"Hypoxia-driven immune escape in the tumor microenvironment","volume":"9","author":"Vito","year":"2020","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.biopha.2022.113544_bib38","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1111\/jcmm.16399","article-title":"Tumour angiogenesis normalized by myo-inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response","volume":"25","author":"El Hafny-Rahbi","year":"2021","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2022.113544_bib39","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1038\/s41467-021-24069-w","article-title":"Phase Ib dose-escalation study of the hypoxia-modifier myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors","volume":"12","author":"Schneider","year":"2021","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2022.113544_bib40","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1073\/pnas.0812381106","article-title":"Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, <em>myo<\/em>-inositol trispyrophosphate","volume":"106","author":"Biolo","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2022.113544_bib41","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/jcmm.14909","article-title":"Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol tris pyrophosphate (ITPP) through enhancement of oxygen delivery by red blood cells","volume":"24","author":"Okni\u0144ska","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"18002","key":"10.1016\/j.biopha.2022.113544_bib42","article-title":"Right ventricular myocardial oxygen partial pressure is reduced in monocrotaline-induced pulmonary hypertension in the rat and restored by myo-inositol trispyrophosphate","volume":"11","author":"Okni\u0144ska","year":"2021","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.biopha.2022.113544_bib43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jacc.2008.06.003","article-title":"Reduction in hemoglobin-oxygen affinity results in the improvement of exercise capacity in mice with chronic heart failure","volume":"52","author":"Watanabe","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113544_bib44","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1152\/japplphysiol.00257.2017","article-title":"The effects of RSR13 on microvascular Po2 kinetics and muscle contractile performance in the rat arterial ligation model of peripheral arterial disease","volume":"123","author":"Watanabe","year":"2017","journal-title":"J. Appl. Physiol."},{"issue":"Suppl. 2","key":"10.1016\/j.biopha.2022.113544_bib45","first-page":"II-351","article-title":"RSR13, a synthetic allosteric modifier of hemoglobin, improves myocardial recovery following hypothermic cardiopulmonary bypass","volume":"100","author":"Kilgore","year":"1999","journal-title":"Circulation"},{"issue":"Suppl. 63","key":"10.1016\/j.biopha.2022.113544_bib46","first-page":"PA1636","article-title":"Voxelotor, which left shifts the oxy-hemoglobin dissociation curve, improves oxygen desaturation in IPF patients during maximal exercise","volume":"54","author":"Vlahakis","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.biopha.2022.113544_bib47","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.21873\/anticanres.11158","article-title":"ITPP treatment of RG2 glioblastoma in a rat model","volume":"36","author":"F\u00f6rnvik","year":"2016","journal-title":"Anticancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2022.113544_bib48","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1002\/ijc.28597","article-title":"Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy","volume":"134","author":"Raykov","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2022.113544_bib49","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ijrobp.2021.02.012","article-title":"Tumor oxygenation by myo-inositol trispyrophosphate enhances radiation response","volume":"110","author":"Grgic","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.biopha.2022.113544_bib50","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.21873\/anticanres.11425","article-title":"Failure of inositol trispyrophosphate to enhance highly effective radiotherapy of GL261 glioblastoma in mice","volume":"37","author":"Iyengar","year":"2017","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2022.113544_bib51","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/cbic.201000619","article-title":"Myo-InositolTrisPyroPhosphate treatment leads to HIF-1\u03b1 suppression and eradication of early hepatoma tumors in rats","volume":"12","author":"Aprahamian","year":"2011","journal-title":"ChemBioChem"},{"issue":"3","key":"10.1016\/j.biopha.2022.113544_bib52","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/jcmm.14092","article-title":"Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models","volume":"23","author":"Tran","year":"2019","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2022.113544_bib53","first-page":"155","article-title":"Development of a methodology for in vivo follow-up of hepatocellular carcinoma in hepatocyte specific Trim24-null mice treated with myo-inositol trispyrophosphate","volume":"35","author":"Ignat","year":"2016","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"issue":"5","key":"10.1016\/j.biopha.2022.113544_bib54","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/SLA.0000000000002431","article-title":"The allosteric hemoglobin effector ITPP inhibits metastatic colon cancer in mice","volume":"266","author":"Limani","year":"2017","journal-title":"Ann. Surg."},{"issue":"23","key":"10.1016\/j.biopha.2022.113544_bib55","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-15-3112","article-title":"Antihypoxic potentiation of standard therapy for experimental colorectal liver metastasis through myo-inositol trispyrophosphate","volume":"22","author":"Limani","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"36","key":"10.1016\/j.biopha.2022.113544_bib56","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1038\/onc.2012.445","article-title":"Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2","volume":"32","author":"Derbal-Wolfrom","year":"2013","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.biopha.2022.113544_bib57","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.febslet.2007.01.079","article-title":"Anti-angiogenic properties of myo-inositol trispyrophosphate in ovo and growth reduction of implanted glioma","volume":"581","author":"Sihn","year":"2007","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.biopha.2022.113544_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.4181","article-title":"Combined endogenous MR biomarkers to assess changes in tumor oxygenation induced by an allosteric effector of hemoglobin","volume":"33","author":"Cao-Pham","year":"2020","journal-title":"NMR Biomed."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222009337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222009337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:38:40Z","timestamp":1791661120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222009337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":58,"alternative-id":["S0753332222009337"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113544","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New potential treatment for cardiovascular disease through modulation of hemoglobin oxygen binding curve: Myo-inositol trispyrophosphate (ITPP), from cancer to cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113544"}}